Journal Information
Vol. 34. Issue 6.
Pages 295-299 (June 1998)
Share
Share
Download PDF
More article options
Vol. 34. Issue 6.
Pages 295-299 (June 1998)
Full text access
Vacuna antineumocócica. Antiguas controversias y nuevas indicaciones (I)
Visits
3605
M. Miravitlles
Corresponding author
marcm@hg.vhebron.es

Correspondencia: Servicio de Neumología. Hospital General Universitari Vall d’Hebron. Pg. Vall d’Hebron, 119-129. 08035 Barcelona.
, J. de Gracia
Servicio de Neumología. Hospital General Universitario Vall d’Hebron. Barcelona
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
D.A. Watson, D.M. Musher, J.W. Jacobson, J. Verhoef.
A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery.
J Infect Dis, 17 (1993), pp. 913-924
[2.]
M. Heidelberger, C.M. McLeod, S.J. Kaiser, B. Robinson.
Anti-body formation in volunteers following injection of pneumococci or their type-specific polysaccharides.
J Exp Med, 83 (1946), pp. 303-320
[3.]
C.M. McLeod, R.G. Hodges, M. Heidelberger, W.G. Bemhard.
Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides.
J Exp Med, 82 (1945), pp. 445-465
[4.]
R. Pallarès, J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P.F. Viladrich.
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona Spain.
N Engl J Med, 335 (1995), pp. 474-480
[5.]
Subdirección General de Prestaciones, Evaluación de Tecnologías Sanitarias.
Ministerio de Sanidad y Consumo Informe sobre vacuna neumocócica.
Med Clin (Barc), 102 (1994), pp. 383-386
[6.]
J.M. García-Arenzana, M. Alcorta, J.L. Díez de Tuesta, P. Idígoras, J. Pérez-Trallero.
Indicación de la vacuna antineumocócica en España.
An Med Intern (Madr), 10 (1993), pp. 116-118
[7.]
V.G. Villarubia, L. Sánchez, M. Álvarez de Mon.
Las nuevas vacunas y la respuesta inmunológica (I) La memoria inmunológica. Respuesta humoral frente a respuesta celular.
Med Clin (Barc), 107 (1996), pp. 146-154
[8.]
M.J. Fine, M.A. Smith, C.A. Carson, F. Meffe, S.S. Sankey, L.A. Weissfeld, et al.
Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.
Arch Intern Med, 154 (1994), pp. 2.666-2.677
[9.]
G.A.W. Bruyn, B.J.M. Zegers, R. Van Furth.
Mechanisms of host defense against infection with Streptococcus pneumoniae.
Clin Infect Dis, 14 (1992), pp. 251-262
[10.]
A. Virolainen, J. Jero, H. Káythy, P. Karma, M. Leinonen, J. Eskola.
Nasopharyngeal antibodies to pneumococcal capsular polysaccharides in children with acute otitis media.
J Infect Dis, 172 (1995), pp. 1.115-1.118
[11.]
E.S. Go, Z.A.K. Bailas.
Anti-pneumococcal antibody response in normal subjects: a meta-analysis.
J Allergy Clin Immunol, 98 (1996), pp. 205-215
[12.]
M.J. Rodrigo, M. Miravitlles, M.J. Cruz, J. De Gracia, M. Vendrell, C. Pascual, et al.
Characterization of specific immunoglobulin G (IgG) and its subclasses (IgGl and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population. Proposal for response criteria.
Clin Diag Lab Immunol, 4 (1997), pp. 168-172
[13.]
J.S. Spika, D.S. Fedson, R.R. Facklam.
Pneumococcal vaccination -controversies and opportunities.
Infect Dis Clin North Am, 4 (1990), pp. 11-27
[14.]
D.S. Fedson, E.D. Shapiro, F.M. LaForce, M.A. Mufson, D.M. Musher, J.S. Spika, et al.
Pneumococcal vaccine after 15 years of use Another view.
Arch Intern Med, 154 (1994), pp. 2.531-2.535
[15.]
G. Bolan, C.V. Broome, R.R. Facklam, B.D. Plikaytis, D.W. Fraser, W.F. Schlech .III.
Pneumococcal vaccine efficacy in selected populations in the United States.
Ann Intern Med, 104 (1986), pp. 1-6
[16.]
E.D. Shapiro, A.T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, et al.
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
N Engl J Med, 325 (1991), pp. 1.453-1.460
[17.]
B.M. Farr, B.L. Johnston, D.K. Cobb, M.J. Fisch, T.P. Germanson, K.A. Adal, et al.
Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study.
Arch Intem Med, 155 (1995), pp. 2.336-2.340
[18.]
J.C. Butler, R.F. Breiman, J.F. Campbell, H.B. Lipman, C.V. Broome, R.R. Facklam.
Pneumococcal polysaccharide vaccine efficacy An evaluation of current recommendations.
JAMA, 270 (1993), pp. 1.826-1.831
[19.]
F.T. Fata, B.C. Herzlich, G. Schiffman, A.L. Ast.
Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B12 levels.
Ann Intern Med, 124 (1996), pp. 299-304
[20.]
P. Plans, P. Garrido, L.I. Salleras.
Coste-efectividad de la vacunación neumocócica en Cataluña.
Rev Esp Salud Pub, 69 (1995), pp. 409-417
[21.]
R. Baltussen, A. Ament, R. Leidl, R. Van Furth.
Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands.
Eur J Publ Health, 7 (1997), pp. 153-161
[22.]
Centers for Disease Control.
Recommendations of the Advisory Committee on Immunization Practices (ACIP) Use of vaccines and immune globulins for persons with altered immunocompetence.
MMWR, 42 (1993), pp. 1-18
[23.]
Task Force on Adult Immunization.
Adult immunizations 1994.
Ann Intrn Med, 121 (1994), pp. 540-541
[24.]
Centers for Disease Control and Prevention.
Prevention of pneumococcal disease Recommendations of the Advisory Committee of Immunization Practices (ACIP).
MMWR, 46 (1997), pp. 1-24
[25.]
Centers for Disease Control.
Pneumococcal polysaccharide vaccine usage United States.
MMWR, 33 (1984), pp. 273-286
[26.]
J.C. Butler, R.F. Breiman, H.B. Lipman, J. Hofmann, R.R. Facklam.
Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine.
J Infect Dis, 171 (1995), pp. 885-889
[27.]
M.A. Mufson, D.F. Hughey, C.E. Tumer, G. Schiffman.
Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination.
Vaccine, 9 (1991), pp. 403-407
[28.]
M. Davidson, L.R. Bulkow, J. Grabman, A.J. Parkinson, C. Chamblee, W.W. Williams, et al.
Immunogenicity of pneumococcal revaccination in patients with chronic disease.
Arch Intern Med, 154 (1994), pp. 2.209-2.214
[29.]
H.B. Konradsen.
Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.
Clin Infect Dis, 21 (1995), pp. 616-620
[30.]
A.M. McBean, J.D. Babish, R. Prihoda.
The utilization of pneumococcal polysaccharide vaccine among elderly medicare beneficiaries, 1985 through 1988.
Arch Intern Med, 151 (1991), pp. 2.009-2.016
[31.]
D.S. Fedson.
Influenzae and pneumococcal vaccination in Canada and the United States, 1980-1993: what can the two countries leam from each other?.
Clin Infect Dis, 20 (1995), pp. 1.371-1.376
[32.]
De Ramón, A.M. Casado, J.L. García Satúe, J. Muñoz Méndez, M. Vázquez Mezquita, J. Fernández Francés, J.M. González Ruiz, et al.
Situación actual de la vacuna antineumocócica: una asignatura pendiente.
Rev Clin Esp, 189 (1991), pp. 82-85
[33.]
Centers for Disease Control.
Pneumococcal and influenza vaccination levels among adults aged > 65 years -United States, 1993.
MMWR, 45 (1996), pp. 853-859
[34.]
T.J. Fletcher, W.S. Tunnicliffe, K. Hammond, K. Roberts, J.G. Ayres.
Simultaneous immunization with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.
Br Med J, 314 (1997), pp. 1.663-1.665
[35.]
F.E. Perry, J.R. Catterall.
The pneumococcus: host-organism interactions and their implications for immunotherapy and immuno-prophylaxis.
Thorax, 49 (1994), pp. 946-950
[36.]
E.A. De Velasco, D. Merkus, S. Anderton, A.F. Verheul, E.F. Lizzio, R. Van der Zee, et al.
Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugated vaccines.
Infect Immun, 63 (1995), pp. 961-968
[37.]
G.S. Giebnik, M. Koskela, P.P. Vella, M. Harris, C.T. Le.
Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjúgate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media.
J Infect Dis, 167 (1993), pp. 347-355
[38.]
C.H. Lu, C.J. Lee, P. Kind.
Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate.
Infect Immun, 62 (1994), pp. 2.754-2.760
[39.]
H. Keythy, H. Ahman, P.R. Rünnberg, R. Tillikainen, J. Eskola.
Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjúgate vaccine is immunogenic in infants and children.
J Infect Dis, 172 (1995), pp. 1.273-1.278
[40.]
P.P. Vella, S. Marburg, J.M. Staub, P.J. Kniskern, W. Miller, A. Hagopian, et al.
Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.
Infect Immun, 60 (1992), pp. 4.977-4.983
[41.]
C.J. Elson, R.B. Taylor.
The suppresive effect of carrier priming on the response to a hapten-carrier conjugate.
Eur J Immunol, 4 (1974), pp. 682-687
[42.]
G.R. Siber.
Pneumococcal disease: prospects for a new generation of vaccines.
Science, 265 (1994), pp. 1.385-1.387
Copyright © 1998. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?